Kid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.
FILE - This Feb. 5, 2021, file photo shows the Pfizer logo displayed at the company's headquarters in New York. Kid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday, Oct. 22, as the U.S. considers opening vaccinations to that age group.
Advisers to the FDA will publicly debate the evidence next week. If the agency ultimately authorizes the shots, the Centers for Disease Control and Prevention will make the final decision on who should receive them. The Biden administration has purchased enough kid-size doses — in special orange-capped vials to distinguish them from adult vaccine — for the nation’s roughly 28 million 5- to 11-year-olds. If the vaccine is cleared, millions of doses will be promptly shipped around the country, along with kid-size needles.
That’s important information considering that hospitalizations of mostly unvaccinated children reached record levels last month. The study isn’t large enough to detect any extremely rare side effects, such as the heart inflammation that occasionally occurs after the second dose, mostly in young men.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Pfizer, BioNTech report high efficacy of COVID-19 booster shot in studyPfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
続きを読む »
Pfizer Says Its Booster Shot Shows 95.6% Efficacy Against Covid-19I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
続きを読む »
Pfizer-BioNTech Covid-19 Booster Shot Was 95.6% Effective in Large Trial, Companies SayThe study was carried out while the highly contagious Delta variant was prevalent, the companies said, suggesting the booster helps protect against the contagious strain.
続きを読む »
Study Finds Children To Be Vectors Of Covid-19 And Emerging VariantsA new study by researchers from Massachusetts General Hospital, Brigham and Women’s Hospital, MIT and Harvard Medical School has found that infants, children and adolescents are equally capable of carrying high levels of live, replicating SARS-CoV-2 in their respiratory secretions.
続きを読む »
India celebrates 1 billion COVID-19 vaccine doses with song and danceIndia celebrated the milestone of administering one billion COVID-19 vaccine doses on Thursday, with the government promoting the achievement in song and video even as a recent drop in inoculations worries healthcare providers.
続きを読む »
NBA player Karl-Anthony Towns on losing 8 relatives from Covid-19“That day changed me as a man,” Karl-Anthony Towns said. “I’m never going to get that innocent young boy back. That’s gone. ... Ever since that day, I feel like the world just made me a little colder.”
続きを読む »